论文信息 - Benefits of rivastigmine on attention in dementia associated with Parkinson disease

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later. Significant benefits of rivastigmine over placebo were seen on all aspects of attention assessed: sustained attention, focused attention, consistence of responding, and central processing speed.

I. McKeith | K. Wesnes | M. Emre | R. Lane | C. Edgar

[1] Günther Deuschl,et al. Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.

[2] M. Emre. Dementia associated with Parkinson's disease , 2003, The Lancet Neurology.

[3] D. Aarsland,et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. , 2003, Archives of neurology.

[4] C G Ballard,et al. Fluctuations in attention , 2002, Neurology.

[5] I. McKeith,et al. Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System , 2002, Dementia and Geriatric Cognitive Disorders.

[6] R Bucks,et al. Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. , 2001, Archives of neurology.

[7] Murat Emre,et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study , 2000, The Lancet.